Welcome to our dedicated page for Neurosense Therapeutics SEC filings (Ticker: NRSN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NeuroSense Therapeutics Ltd. filings document foreign private issuer disclosures for a clinical biotechnology company developing PrimeC for severe neurodegenerative diseases. Its Form 6-K reports cover clinical and regulatory updates, PrimeC patent protection, scientific publication of PARADIGM trial results, Nasdaq continued-listing notifications, and incorporation of selected reports into Form S-8 and Form F-3 registration statements.
The company’s regulatory record also addresses shareholder voting matters, including amendments to registered share capital, capital-structure disclosures, governance changes, material agreements, operating and financial results, and leadership or advisory arrangements tied to the PrimeC development program.
NeuroSense Therapeutics Ltd. officer Hagit Binder, serving as General Manager, has filed a Form 3 showing her current equity interests in the company. She directly holds ordinary shares listed in several line items, including 12,836 shares, 32,000 shares and 266,970 shares.
Binder also holds options to purchase 36,000 ordinary shares at an exercise price of $1.9900 per share, expiring on October 12, 2032; these options are fully vested and exercisable. In addition, she holds 10,000 restricted share units that are scheduled to vest on April 1, 2026. Certain plan-related securities are held through a trustee to qualify for tax benefits under Israeli law.
NeuroSense Therapeutics Ltd. director Claiborne Cary J filed an initial ownership report, detailing existing equity positions rather than new trades. The filing lists options to purchase 72,000 Ordinary Shares at an exercise price of $1.43 per share, expiring on March 10, 2032, which are fully vested and exercisable. It also discloses multiple blocks of Ordinary Shares held directly, including restricted shares that vest on December 30, 2026 and January 30, 2027, with potential accelerated vesting if specified business milestones are achieved.
NeuroSense Therapeutics Ltd. director Golan Roy filed an initial Form 3 reporting his beneficial ownership of Ordinary Shares. This filing establishes his starting equity position as an insider of the company.
Footnotes indicate that certain restricted shares were granted under NeuroSense’s 2018 Share Incentive Plan and are held through a trustee to qualify for Israeli Section 102 tax benefits. These restricted shares are scheduled to vest on December 30, 2026 and January 30, 2027, subject to his continued service, with potential accelerated vesting if a specified business milestone described in his restricted share agreements is achieved.
NeuroSense Therapeutics reported that results from its multinational Phase 2b trial of PrimeC in amyotrophic lateral sclerosis (ALS) have been published in JAMA Neurology. The randomized, double-blind, placebo-controlled study enrolled 68 participants and included a 6‑month blinded period followed by a 12‑month open‑label extension.
Participants who received PrimeC from the outset maintained a 7.92‑point functional advantage on the ALSFRS‑R scale at 18 months, representing over 36% slowing of disease progression (p=0.007), with the largest benefit in the bulbar domain (p=0.001). ALS complication‑free survival showed a 64% relative risk reduction favoring early treatment (p=0.02).
The trial also showed biological activity consistent with PrimeC’s multi‑pathway mechanism, including favorable changes in iron metabolism markers and significant downregulation of ALS‑associated microRNAs. These data, together with good safety, helped shape NeuroSense’s Phase 3 trial of PrimeC, which has received FDA clearance to proceed.
NeuroSense Therapeutics Ltd. held a Special Meeting of Shareholders on March 10, 2026. At this meeting, shareholders approved a resolution to amend the company’s articles of association in order to increase the company’s registered share capital, expanding the amount of equity the company is authorized to issue in the future.
The report also states that this information is incorporated by reference into NeuroSense’s existing registration statements on Form S-8 and Form F-3, meaning those shelf and employee benefit registrations now reflect the updated corporate authorization.
NeuroSense Therapeutics reported new long-term survival data from its completed Phase 2b trial of PrimeC in amyotrophic lateral sclerosis (ALS). Patients treated continuously with PrimeC showed an estimated median survival of 36.3 months versus 21.4 months for those initially on placebo, an improvement of over 14 months and about a 70% increase in median survival. A log-rank test showed statistically significant separation between treatment arms (p = 0.0218), and a Cox model associated PrimeC with a 65% reduction in risk of death versus placebo (hazard ratio 0.35; 95% CI: 0.17–0.71; p = 0.0037). The randomized, double-blind, placebo-controlled trial in 68 ALS patients had previously demonstrated slowed disease progression and favorable safety. NeuroSense believes these survival results strengthen the case for advancing PrimeC into pivotal late-stage development.
NeuroSense Therapeutics Ltd. is asking shareholders to approve an amendment to its Articles of Association to increase its registered share capital to 200 million ordinary shares, no par value. The registered share capital is currently 90 million ordinary shares.
As of February 11, 2026, the company had approximately 39 million ordinary shares available for future issuance after accounting for outstanding options, warrants and RSU grants. The board states that the larger share pool is intended to maintain flexibility for strategic financings and other issuances to support continued development of PrimeC, including planned Phase 3 activities.
The proposal will be presented at a Special Meeting of Shareholders scheduled for March 10, 2026, at 4:00 p.m. (Israel time) in Herzliya. Shareholders of record at the close of business on February 17, 2026 are entitled to notice and to vote, and the board unanimously recommends voting in favor.
NeuroSense Therapeutics filed a Form 6-K to highlight a new Australian patent grant for its lead drug candidate PrimeC. The Australian Patent Office granted Patent No. 2022370513, covering compositions combining ciprofloxacin and celecoxib, extending patent protection for PrimeC in Australia through October 2042 and reinforcing a previously granted U.S. patent.
PrimeC is a proprietary fixed-dose, extended-release oral formulation designed to deliver ciprofloxacin and celecoxib in a synchronized way, targeting multiple disease pathways in amyotrophic lateral sclerosis (ALS) and potentially Alzheimer’s disease and other neurodegenerative conditions. NeuroSense describes PrimeC as Phase 3-ready in ALS, following positive Phase 2b results and FDA clearance of a pivotal Phase 3 protocol.
The company frames this Australian patent as part of a broader global intellectual property strategy intended to support the long-term development and potential commercialization of PrimeC across major markets.
NeuroSense Therapeutics Ltd. has filed a Form F-3 shelf registration to offer up to $150,000,000 of securities, including ordinary shares, warrants, debt securities, subscription rights and units. This base shelf also supports a Capital on Demand at-the-market program of up to $6,525,000 in ordinary shares through JonesTrading, which will receive a 3% commission on gross sales.
The filing carries forward $85,778,066 of unsold securities from a prior F-3 and deems that earlier offering terminated once this new registration is effective. NeuroSense is a clinical-stage biotech focused on neurodegenerative diseases, led by ALS candidate PrimeC, which has shown positive Phase 2b data and is being advanced toward a planned Phase 3 trial. The company notes substantial doubt about its ability to continue as a going concern, highlighting the importance of future financings under this shelf and ATM.
NeuroSense Therapeutics Ltd. filed a Form 6-K as a foreign private issuer to report that it held a Special Meeting of Shareholders on December 30, 2025. The filing states that shareholders approved certain resolutions at the meeting, but does not detail the specific matters that were voted on. The report, excluding the fourth paragraph in Exhibit 99.1, is incorporated by reference into the company’s existing registration statements on Form S-8 and Form F-3, meaning this information becomes part of those securities registration documents.